"The fourth quarter capped a transformative year at Apollo, during which we drove increased utilization of our innovative therapeutic endoscopy portfolio, positioned the Company to expand our reach ...

AUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, ...

The FDA cleared Apollo Endosurgery’s SuMO endoscopic tissue access and resection system, which allows surgeons to remove large, flat precancerous gastrointestinal lesions and polyps during endoscopy ...

Apollo Endosurgery has announced it has added Richard J. Meelia, former CEO and chairman of Covidien, to its board of directors, according to a news release. Apollo Endosurgery develops therapeutic ...

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. ("Apollo") (Nasdaq: APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced financial ...

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the ...

AUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, ...

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader Sign up ...

Apollo Endosurgery, Inc. (NASDAQ:APEN) just released its latest quarterly results and things are looking bullish. Sales crushed expectations at US$13m, beating expectations by 29%. Apollo Endosurgery ...

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Apollo Endosurgery, Inc. (NASDAQ:APEN) is a small-cap stock with a market ...

While other large med-tech companies are slimming their portfolios, Boston Scientific Corp. plans to beef its up considerably with the acquisition of Apollo Endosurgery Inc. for $10 per share for the ...